Advances in researches on hormonal refractory prostate cancer / 中华男科学杂志
National Journal of Andrology
; (12): 57-60, 2007.
Article
in Zh
| WPRIM
| ID: wpr-289045
Responsible library:
WPRO
ABSTRACT
In China, the incidence of prostate cancer has been increasing in recent years. Hormonal therapy has been the mainstay of the therapeutic options for metastatic diseases for many years. But many metastatic tumors progress at a median of two to five years and become hormonal refractory prostate cancer (HRPC). This article summarizes in the advances of diagnostic criteria, molecular biological features, prediction markers, new therapeutic agents and further researches to be undertaken concerning HRPC.
Full text:
1
Index:
WPRIM
Main subject:
Pathology
/
Pharmacology
/
Prostatic Neoplasms
/
Biomarkers, Tumor
/
Drug Resistance, Neoplasm
/
Diagnosis
/
Drug Therapy
/
Androgen Antagonists
Type of study:
Diagnostic_studies
/
Prognostic_studies
Limits:
Aged
/
Humans
/
Male
Language:
Zh
Journal:
National Journal of Andrology
Year:
2007
Type:
Article